quarter call. XXXX Thank welcome you, TransMedics Good and earnings afternoon, second to everyone, Brian.
As Stephen Financial me today Gordon, joining is Chief Officer. our always,
important and XXXX was growth initiatives. first of as operational several an strategic successfully executed period on TransMedics The for half we
our being XQ culminated have highest Our efforts revenue in quarter-to-date.
We with agreements offering, this a balance both our propel sheet long-term. entered and convertible two trajectory into our that for on earlier will successful we growth further and short also buttressed acquisitions debt week us
XQ, and room a three schedule accelerated position meet NOP opened momentum further Operationally, all our through This on sterilization across organs. capacity. and demand In growing OCS. clean and partnership better second production we to and will significant demonstrated clinical new enhancing large we commercial adoption the high us throughput for secured our
U.S. and million, up our achieved sales performance. Now year-over-year XXX% let quarter, growth specifics XXX% year-over-year of representing second the me cover XX% In revenue, $XX of revenue over XQ growth $X.X million. XQ OUS the $XX.X we with million total 'XX. in to growing represented XX% sales
P&L down section detail cover We today's the his we Stephen benefit call. also demonstrated in as continued leverage. the will operating increasing from improvement of
sheet our TransMedics a of buttressed convertible us issuing $XXX million the at and approximately terms, up by to we highly net enable in Importantly, standing debt favorable invest network. balance which logistics aviation provided to
in by volume in consecutive new quarters. many and lungs. three the volume was past heart meanwhile, and quarters. sequentially across all highest for another also quarter, XQ quarter lung we've the watermark saw sixth represented organs the liver, case eight first increased driven high in for We achieved growth for heart growth Liver the
continued this We lung hope growth to forward. early momentum on build to and are see continue going planning to
NOP, OCS liver, we were transplant number liver In our NOP. grew and also active In users. XX and of using used heart programs and the XQ, programs strategy, which of growth line outline with XX lung OCS
of used XX active OCS were by We're programs lung For recovery heart, repeat of that lung users. five early There XX XX program. there NOP, users. signs the NOP, of and were were and OCS which encouraged of used programs were our that which
to continuing of the on our focused XX business XX grow remain next months. we over lung to segment However,
In lung On approximately XX% per NOP. NOP. volume came were of our from of NOP U.S. heart case cases XX% basis, contribution, and organ from XX% approximately of of a total terms of liver, XX%
the in before, to to share lion's expect drive we going As continue of U.S. our the NOP the stated we forward. revenue
In we in right new our clean more adding XQ, room production capacity demand for on to meet initiated schedule, OCS.
new building space. room first shifts training We the currently second are and clean up and for the
in We new expect perfusion per it's fully modules XX,XXX once OCS over room this year to produce clean staffed.
qualifying significant our add to enhance second will able are forward. partner. we capacity XQ, by sterilization large a sterilization in further Finally, capacity throughput This going
demonstrated business. the of growth XQ trajectory have again Our our once results
NOP call, XQ our industry in past the shown current and the the have model unscaled months the described United our operating inefficient in us experience we model As XX States over how organ transplant dedicated logistics for network. U.S. committed in launching efficient for is developing national transplantation more TransMedics national as to a organ by Aviation logistics transportation model is. the TransMedics the first
directly goal to end-to-end transplant manage all our help half the to NOP recipient U.S. transplant XXXX. to to is by the the U.S. the volume a Our of broadly. This donor will control and to growth in remove logistics volumes second bottleneck process entire critical of
We that seeing are of today. NOP availability fragmented air transplant flight the making being the limited this older importantly, and investment to is the outpace capacity, radius charter volumes because starting the we are used
our operational represents network capacity. logistics Please U.S. color recently NOP acquire aviation next the allow and reach This the designed we acquisition premier national more and strategy the that this a important to me service months. Summit to the over several flight on end, operators. to provide envision a element how next definitive cornerstone we expand transplant signed to I'm steps getting Aviation, dedicated that one of To a acquisition to charter our of create agreement delighted
or to and for of VP satisfactory current Aviation assume timeline perspective, close President this is of Ben in subject XXXX intend to the perspective veteran expected timing Summit QX, and a TransMedics Walton, closing a acquisition the From we a of conditions of fulfillment Services. role
entire and the team to from operations and the majority transition TransMedics. pilots the maintain to intend also of We Summit
TransMedics establishing eight here dispatch currently and capable from is deploy Continental will Aviation fleet team aviation in Further, of a hubs Andover U.S. dedicated Andover, the of center command digital This that national XXX% the approximately TransMedics the Massachusetts. center covering be located will efficiently logistics in
use to approach data and to maximize the of operations. driven TransMedics network continue will logistical coverage refine to efficiency a the national transplant We
We begun fleet first operational have XXXX. also by initially several the the reach XX goal target TransMedics acquiring to of to process to aircrafts of airplanes expand half of our having XX additional
an we intend long-term TransMedics bring support future fleet. our Subject future strategic success. for advantage existing flight the for school pilots the is to believe strongly ensure Summit closing, to the of We trained to foreseeable operations to supply important this
operations to of the we transition transition have in XXX% Montana intend down part Summit, we our dispatch with and transplant a agreement to charter wind transplant As aviation TransMedics short focused national a dispatch aircraft to Bozeman, which And Andover operations management will center. period private maintain finally, complement operations. intend to to all command our we during and
XX continuing specifically, front grow reach Especially to we in As U.S., of our coverage NOP and workflow the to footprint field to scaling NOP to the process. services months to must growth team NOP invest the the infrastructure working surgical continue logistics of maximize our we or logistics meet on and in revamping us. Meanwhile, and across and grow dispatch we our expanding demand U.S. the to efficiency clinical significant intend throughout is in also next the staffing the the XX to NOP are clinical growing for and meet the
year a transplants transplant we I've per achieve which our to devised goes growing stated publicly before, NOP are strategy at volume reach multifaceted TransMedics As X next as we over goal, XX,XXX years. follows. To focusing on the this
leadership enable workflow clinical volume. scalability First, maintain is of in This will by the OCS developing that a the technological clinical platform for optimized management. field NOP and next-gen case
our the TransMedics expand And for OCS the Second, platform. finally, indications offering. clinical product overall expand
and recently IP-related Life. above Bridge the technologies two on to from we execute to strategy, perfusion To assets acquired
cover heart The clinical to warm elements OCS criteria currently was the perfusion to unique technology indications to using transplant. expand transplant. We that supplement hearts our And for to product first development, next-gen preserved the technologies second plan storage. perfusion for OCS static cold these our accelerate platform standard use lung of merely and cold OCS heart today heart LifeCradle are was EVOSS
these may in a support better momentum in technology our our advantage the and U.S. the long-term And to intellectual the programs using to expand that of breadth for to perfusion to technology, share cold effort be worldwide. there finally, We near property hope development reignite broad believe have more about then for future. the lung We machine value portfolio. and perfusion
quarters and the performance demonstrated NOP. for the demand have commercial Our OCS past growing over and X significant
in this and and 'XX. we ability that and We significantly to transplants have the we goal reach the years. transplant next is in similar to results is beginning, deliver our believe successfully again track grow that to our revenue important on only to over determined strongly are 'XX, X XX,XXX note volume of our It demonstrated we are annual
NOP We I aviation it the operations and time and scale grow logistics time and must, the of the as to the however, to buttress level. following. NOP integration describe our the next capacity for take infrastructure to can allow our best
growth to see must be and the to acclimatization achieving months a our to time and as stage to wave the very path XXXX pace growth four needed integration target. stage ourselves TransMedics for next growth we or summit, next beyond. We our high for to On long-term allow the ready ensure six or in critical
$XXX potential from are for $XXX a be year to Given over between annual previously our 'XX full-year representing million results, strong growth $XXX and balanced our million, $XXX XXXX $XX million XXXX communicated million revenue million challenges, up XQ $XXX total increasing we the guidance to scalability and of full our revenue. and million HX guidance to with
turn to the me results the financial let detailed Gordon that, Stephen With call quarter. to for the cover